COEPCoeptis Therapeutics Holdin...

Nasdaq coeptispharma.com


$ 0.39 $ 0.00 (1.2 %)    

Wednesday, 08-May-2024 13:15:15 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 0.3795
$ 0.39
$ 0.00 x 0
$ 0.42 x 100
$ 0.39 - $ 0.39
$ 0.29 - $ 2.19
78,726
na
13.7M
$ 0.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-25-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-29-2023 12-31-2022 10-K
6 11-18-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 04-08-2022 12-31-2021 10-K
10 11-16-2021 09-30-2021 10-Q
11 09-14-2021 06-30-2021 10-Q
12 07-30-2021 03-31-2021 10-Q
13 03-31-2021 12-31-2020 10-K
14 12-10-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 coeptis-therapeutics-adds-autoimmune-indications-to-exclusive-license-agreement-with-university-of-pittsburgh-for-snap-car-t-and-snap-car-nk

Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to...

 collective-audience-and-3-other-stocks-under-1-insiders-are-buying

The Dow Jones index closed lower by around 100 points on Wednesday. When insiders purchase or sell shares, it indicates their c...

 coeptis-therapeutics-sets-sights-on-expanding-cancer-and-autoimmune-treatments-in-2024

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company dev...

 coeptis-therapeutics-announces-research-demonstrating-the-potential-of-snap-car-t-cells-to-reduce-tumor-burden-and-growth-in-her2-and-cd20-expressing-cancers-will-be-presented-at-sitc-2023

 Poster presentation describes the development of SNAP CAR platform technology as a "universal" CAR therapy with the po...

 coeptis-therapeutics-has-expanded-its-exclusive-license-agreement-with-the-university-of-pittsburgh-to-include-the-snap-car-technology-platform-in-natural-killer-cells

This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T-Ce...

 ladenburg-thalmann-initiates-coverage-on-coeptis-therapeutics-with-buy-rating-announces-price-target-of-3

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Coeptis Therapeutics (NASDAQ:COEP) with a Buy rating and ann...

 coeptis-therapeutics-phase-1-trials-of-dvx201-for-relapsedrefractory-acute-myeloid-leukemia-or-high-risk-myelodysplastic-syndrome-and-hospitalized-covid-19-patients-showed-no-dose-limiting-toxicities-cytokine-release-syndrome-or-infusion-toxicities

Coeptis Expects To Report Topline Safety And Efficacy Data From The Full Patient Population In Q1 Of 2024

 biorestorative-therapies-and-3-other-stocks-under-3-insiders-are-buying

The Dow Jones closed lower by over 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence...

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 210 companies reached new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION